AstraZeneca–Sun Pharma Partner to Expand Access to Hyperkalaemia Drug SZC in India

AstraZeneca and Sun Pharma Partner to Market Hyperkalaemia Drug in India

AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a strategic partnership to widen access to Sodium Zirconium Cyclosilicate (SZC) —a key therapy for managing hyperkalaemia , a potentially life-threatening elevation of potassium levels often seen in chronic kidney disease (CKD) and heart failure (HF) patients. The agreement is aimed at strengthening national reach through a dual-brand expansion model.

Dual-Brand Strategy for Wider Penetration

Under the collaboration, both companies will independently market SZC across India. AstraZeneca will continue to sell the drug under its global brand Lokelma , while Sun Pharma will introduce its own brand, Gimliand , to expand penetration in varied clinical settings. The model is expected to increase accessibility without altering the drug’s formulation or ownership.

AstraZeneca Retains Regulatory and IP Control

Despite the shared marketing responsibilities, AstraZeneca will retain intellectual property rights, marketing authorisation, and the import licence for SZC. Company officials noted that the arrangement leverages Sun Pharma’s extensive field force and distribution network, improving access for patients requiring routine potassium management.

Addressing a High-Burden Clinical Condition

Hyperkalaemia remains a significant challenge in India’s renal and cardiac disease landscape. Estimates indicate that the condition affects up to 50% of CKD patients and 42% of chronic HF patients , particularly those undergoing RAAS inhibitor therapy . Uncontrolled potassium levels can cause muscle weakness, arrhythmias and fatal cardiac events, making rapid and reliable treatment essential.

Exam Oriented Facts

• SZC is prescribed to manage hyperkalaemia in CKD and HF patients.

• AstraZeneca brand: Lokelma ; Sun Pharma brand: Gimliand .

• AstraZeneca retains IP, marketing authorisation and import rights .

• Hyperkalaemia impacts ~50% of CKD and 42% of HF patients.